lyophilization raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-25 and is reviewed periodically as new material appears.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3.4 to 3.6 kDa | Depends on whether the affinity complex is attached |
| Appearance | White to off-white lyophilized powder | Freeze-dried solid, often in a sealed vial |
| Solubility | Soluble in water and aqueous buffers | Dissolution rate varies with pH and buffer salt |
| Typical storage | Below minus 20 degrees Celsius, dry and dark | Dissolved material is usually kept cold and used promptly |
| Common analytical methods | Reversed-phase HPLC and mass spectrometry | Peptide mapping and amino acid analysis add sequence detail |
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Prolidase deficiency (PD) is an extremely uncommon autosomal recessive disorder associated with collagen metabolism that affects connective tissues and thus a diverse array of organ systems more broadly, though it is extremely inconsistent in its expression. Collagen is a structural protein found i.a. in bone, skin and connective tissues that is broken down into iminodipeptides at the end of its lifecycle. Of these dipeptides, those containing C-terminal proline or hydroxyproline would normally be broken down further by the enzyme Prolidase, recovering and thus recycling the constituent amino acids. Due to a genetic defect, prolidase activity in individuals with PD is either knocked out or severely reduced. Those affected therefore eliminate excessive amounts of iminodipeptides in their urine, wasting this precious resource, with debilitating effects.
== Further reading == (in French) Bernardi AC (1858). Monographie du genre Conus (in French). Berschauer D. (2010). Technology and the Fall of the Mono-Generic Family The Cone Collector 15: pp. 51–54 Bruguière JG (1792). "Histoire Naturelle des Vers". Encyclopédie Méthodique. Vol. 1. Paris: Panckoucke. pp. 345–757. Clench WJ (1942). "The Genus Conus in the Western Atlantic". Johnsonia. 1 (6): 1–40. Coltro Jr J (2004). "New species of Conidae from northeastern Brazil (Mollusca: Gastropoda)". Strombus. 11: 1–16. Flomenbaum NE, Goldfrank LR, Hoffman RS, Howland MA, Lewin NA, Nelson LS, eds. (28 March 2006). Goldfrank's Toxicologic Emergencies (8th ed.). New York: McGraw-Hill. ISBN 978-0-07-143763-9. Franklin JB, Subramanian KA, Fernando SA, Krishnan KS (2009). "Diversity and Distribution of Conidae from the Tamil Nadu Coast of India (Mollusca: Caenogastropoda: Conidae)". Zootaxa. 2250: 1–63. doi:10.11646/zootaxa.2250.1.1. Franklin JB, Fernando SA, Chalke BA, Krishnan KS (2007). "Radular morphology of Conus (Gastropoda: Caenogastropoda: Conidae) from India" (PDF). Molluscan Research. 27 (3): 111–122. doi:10.11646/mr.27.3.1. García EF (2006). "Conus sauros, a new Conus species (Gastropoda: Conidae) from the Gulf of Mexico". Novapex. 7: 71–76. Gmelin, J. F. 1791. Systema naturae per regna tria naturae. Editio decima tertia. Systema Naturae, 13th ed., vol. 1(6): 3021–3910. Lipsiae. Kiener LC (1845). "Genre Cone. (Conus, Lin.).". Spécies Général et Iconographie des Coquilles Vivantes. Vol. 2. pp. 1–111. Kohn A. A. (1992). "Chronological Taxonomy of Conus, 1758-1840".
In June 2013, two biosimilar versions (Inflectra and Remsima) were submitted for approval in the European Union, by Hospira and Celltrion Healthcare respectively. Both had a positive opinion from European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for sale in the European Union (EU). Celltrion obtained marketing authorization approval (MAA) from 27 EU countries and 3 EEA (European Economic Area) countries by September 2013. Inflectra was approved for use in the European Union in September 2013, and Remsima was approved for use in the European Union in October 2013. In Japan, Celltrion received marketing authorization for Remsima from Japan's Ministry of Health, Labour and Welfare (MHLW) in July 2014. In India, Epirus Biopharmaceuticals obtained approval to produce biosimilar infliximab under the brand name "Infimab" (trail name BOW015). The US Food and Drug Administration (FDA) approved Celltrion/Hospira/Pfizer's Inflectra (infliximab-dyyb) in April 2016. The FDA approved Samsung Bioepis Co., Ltd.'s Renflexis (infliximab-abda) in April 2017. Biogen released another biosimilar, Flixabi, which was approved in Germany, the UK, and the Netherlands. Flixabi was approved for use in the European Union in May 2016. In December 2017, Ixifi (infliximab-qbtx) was approved in the United States. Zessly was approved for use in the European Union in May 2018. In December 2019, Avsola (infliximab-axxq) was approved in the United States. Avsola was approved for medical use in Canada in March 2020.
== Medical Significance == Pathogenic mutations in this gene have been associated with a number of diseases, including Developmental and epileptic encephalopathy 71 (DEE71), CASGID syndrome, and Global developmental delay, progressive ataxia, and elevated glutamine (GDPAG).
Sources: en.wikipedia.org
== External links == "Prokineticin Receptors". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2011-05-16. Retrieved 2007-10-25. PROKR1+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH) PROKR2+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
The use of pulses of different durations, frequencies, or shapes in specifically designed patterns or pulse sequences allows production of a spectrum that contains many different types of information about the molecules in the sample. In multi-dimensional nuclear magnetic resonance spectroscopy, there are at least two pulses: one leads to the directly detected signal and the others affect the starting magnetization and spin state prior to it. The full analysis involves repeating the sequence with the pulse timings systematically varied in order to probe the oscillations of the spin system are point by point in the time domain. Multidimensional Fourier transformation of the multidimensional time signal yields the multidimensional spectrum. In two-dimensional nuclear magnetic resonance spectroscopy (2D-NMR), there will be one systematically varied time period in the sequence of pulses, which will modulate the intensity or phase of the detected signals. In 3D-NMR, two time periods will be varied independently, and in 4D-NMR, three will be varied. There are many such experiments. In some, fixed time intervals allow (among other things) magnetization transfer between nuclei and, therefore, the detection of the kinds of nuclear–nuclear interactions that allowed for the magnetization transfer. Interactions that can be detected are usually classified into two kinds. There are through-bond and through-space interactions.
== Episode 2: Second Opinions == Sadie Gonzalez is a 7 year old little girl from Queens, NY, with a severe brain disorder. Sadie suffers from very frequent seizures that have resulted in a slight speech and mobility impediment. Her mother recounts the first time Sadie had a seizure being the morning of the 29th of December, when Sadie was 6 years old. The seizures stopped for two months and in late February Sadies seizures started to violently progress into daily visible seizures that will affect different parts of her body at a time. At the time of recording the episode, Sadie was having a motor seizure almost every couple of minutes. Sadie was admitted into the Columbia Presbyterian where multiple MRI’s were done showing no signs of brain damage or brain tumors. These results along with her symptoms led some physicians to believe she had Rasmussen’s. Rasmussen’s Encephalitis, explained by Dr. Lisa Sanders, is characterized by the chronic inflammation caused by T-Lymph white blood cells to invade half of the brain and destroy it. The only sure treatment for Rasmussen’s is a hemispherectomy, where the corpus callosum is severed and separated the diseased side of the brain from the healthy side. This procedure can result in loss of vision in one eye, losing the ability to move one half of her body, or losing the ability to speak. If Sadie actually does have this disorder and undergoes the procedure, then half of the brain can spread into the second half, causing the brain to deteriorate. The parents of Sadie reach out to Dr.
Sources: en.wikipedia.org
=== Genes are commonly interrupted by introns that must be removed by RNA splicing === Analysis of mature eukaryotic messenger RNA molecules showed that they are often much smaller than the DNA sequences that encode them. The genes were shown to be discontinuous, composed of sequences that are not present in the final mature RNA (introns), located between sequences that are retained in the mature RNA (exons). Introns were shown to be removed after transcription through a process termed RNA splicing. Splicing of RNA transcripts requires a highly precise and coordinated sequence of molecular events, consisting of (a) definition of boundaries between exons and introns, (b) RNA strand cleavage at exactly those sites, and (c) covalent linking (ligation) of the RNA exons in the correct order. The discovery of discontinuous genes and RNA splicing was entirely unexpected by the community of RNA biologists, and stands as one of the most shocking findings in molecular biology research.
As the continental plates moved closer together, fragments of oceanic crust, islands, and other continental masses collided with the eastern margin of ancestral North America. By this time, plants had appeared on land, followed by scorpions, insects, and amphibians. The ocean continued to shrink until, about 270 million years ago, the continents that were ancestral to North America and Africa collided during the formation of the supercontinent Pangea. Because North America and Africa were once geographically connected, the Appalachians formed part of the same mountain chain as the Little Atlas in Morocco. This mountain range, known as the Central Pangean Mountains, extended into Scotland, before the Mesozoic Era opening of the Iapetus Ocean, from the North America/Europe collision (See Caledonian orogeny). By the end of the Mesozoic Era, the Appalachian Mountains had been eroded to an almost flat plain. It was not until the region was uplifted during the Cenozoic Era that the distinctive topography of the present formed. Uplift rejuvenated the streams, which rapidly responded by cutting downward into the ancient bedrock. Some streams flowed along weak layers that define the folds and faults created many millions of years earlier. Other streams downcut so rapidly that they cut right across the resistant folded rocks of the mountain core, carving canyons across rock layers and geologic structures.
== Traffic congestion == TomTom, the Dutch manufacturer of land navigation products, ranked Bangkok as the second-most traffic-clogged city of 189 cities studied worldwide. Mexico City topped the rankings. Other ASEAN cities listed were Jakarta, third, and Singapore at 55. The INRIX 2016 Global Traffic Scorecard ranked Thailand as the most congested nation of 38 studied for "average peak hours spent in congestion". Thais spent an average of 61 hours in 2016 stuck in traffic. Bangkok was ranked 11 of 100 cities for "peak hours spent in congestion", 64 hours. Based on 2015 data, Dutch navigation and digital mapping company, TomTom NV, ranked Bangkok number two in a listing of the 174 most traffic congested cities worldwide (1=most congested; 174=least congested). Mexico City ranked number one. No other ASEAN cities made the list.
Healthcare centres, including clinics, doctor's offices, urgent care centers and ambulatory surgery centers, serve as first point of contact with a health professional and provide outpatient medical, nursing, dental, and other types of care services.
Sources: en.wikipedia.org
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.
In common usage the name without the affinity complex is often equated with MOD GRF 1-29, a fragment carrying four stabilizing substitutions. Strictly speaking, the term originally referred to the albumin-binding version. The overlap in naming causes frequent ambiguity in both informal and technical writing.
Reversed-phase chromatography separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the molecular mass and detects modifications such as oxidation. Sequence-level checks rely on peptide mapping or amino acid analysis when stronger confirmation is needed.
The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.